ASCO 2026 Redefines Cancer Survivorship: From Survival to Living Well Across the Entire Cancer Journey
Key Insights
ASCO 2026 emphasized that cancer survivorship begins at diagnosis and extends through treatment, long-term follow-up, and metastatic disease, shifting focus from survival alone to quality of life.
ctDNA (search) and molecular residual disease monitoring are emerging as transformative tools for personalized surveillance, with postoperative ctDNA positivity linked to higher recurrence risk in resected NSCLC.
GLP-1 receptor agonists (search) were associated with lower metastasis rates across multiple cancer types, including lung (10% vs 22%) and breast (10% vs 20%), compared with gliptins.
The American Society of Clinical Oncology (ASCO) 2026 Annual Meeting delivered a resounding message: success in oncology can no longer be measured solely by tumor response and survival statistics. A growing consensus among researchers and clinicians holds that cancer survivorship must encompass the whole person across the entire cancer journey—from diagnosis through active treatment, long-term follow-up, and even metastatic disease.
"For decades, success in oncology has largely been measured by tumor response, disease-free survival, progression-free survival, and overall survival," noted Dr. Muna Al-Khaifi, GP Oncologist at Mount Sinai Hospital, Sinai Health, in reflections on the meeting. "However, one of the strongest messages emerging from ASCO 2026 was that cancer care must extend beyond treating disease to supporting the whole person throughout the entire cancer journey."
Redefining Survivorship Across the Continuum
ASCO 2026 challenged the traditional definition of survivorship by explicitly including patients living with metastatic disease. The TROPION-Breast02 trial exemplified this shift, evaluating the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) as a potential first-line treatment compared with standard chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (search) (TNBC).
TNBC has historically been difficult to treat and often associated with significant treatment-related toxicity. In the metastatic setting, survivorship is not only about extending life but also preserving quality of life. By establishing a more targeted and effective standard of care earlier in the treatment journey, researchers hope to provide patients with more time while reducing the burden of widespread side effects often associated with traditional chemotherapy.
Personalized Surveillance: ctDNA (search) and Molecular Residual Disease
One of the most exciting areas discussed at the meeting was the expanding role of circulating tumor DNA (ctDNA (search)) and molecular residual disease (MRD) monitoring. Multiple sessions explored how liquid biopsy technologies may transform survivorship care by identifying microscopic traces of cancer DNA in the bloodstream months or even years before recurrence becomes visible on conventional imaging.
A systematic review and meta-analysis evaluating postoperative ctDNA (search)-detected molecular residual disease in resected non-small cell lung cancer (search) (NSCLC), encompassing 38 studies, found that ctDNA positivity was associated with a higher risk of early recurrence, while ctDNA negativity predicted more durable remission. These findings support ctDNA's role in postoperative surveillance.
Additional data demonstrated how ctDNA (search)-guided treatment approaches may help clinicians escalate or de-escalate adjuvant therapies more effectively. Among patients with Stage III colorectal cancer, those who were ctDNA-negative after treatment experienced significantly improved disease-free survival, particularly when combined with healthy lifestyle modifications.
Weight Management and Metabolic Health: GLP-1 Receptor Agonists (search)
Several ASCO 2026 presentations explored obesity, metabolic health, and emerging evidence surrounding GLP-1 receptor agonists (search). Research presented at the meeting suggested that individuals with Stage I, II, or III lung, breast, colorectal, or liver cancer who were taking a GLP-1 medication may have a lower risk of disease progression to Stage IV compared with individuals taking gliptins.
Rates of metastasis were notably lower among individuals receiving GLP-1 medications: lung cancer (10% versus 22%), breast cancer (10% versus 20%), colorectal cancer (13% versus 22%), and liver cancer (19% versus 28%). For prostate, pancreatic, and kidney cancers, metastasis rates were also lower among those taking GLP-1 medications, although these differences did not reach statistical significance.
Ongoing research is exploring several possible mechanisms, including direct effects on cancer cells and the tumor microenvironment, modulation of immune responses, reduction of chronic inflammation, and alterations in cancer cell metabolism and energy utilization.
Managing Menopause, Sleep, and Quality of Life
The lidERA study demonstrated that giredestrant, an investigational oral selective estrogen receptor downregulator, reduced the risk of recurrence more effectively than tamoxifen or an aromatase inhibitor in women with early-stage hormone receptor-positive, HER2-negative breast cancer following surgery. The risk of developing metastatic disease was 42% lower among premenopausal women and 24% lower among postmenopausal women treated with giredestrant.
Researchers also presented findings from the OASIS-4 subgroup analysis evaluating elinzanetant's effects on sleep disturbance and menopause-related quality of life in women with breast cancer experiencing vasomotor symptoms while receiving endocrine therapy. Elinzanetant consistently improved sleep disturbance and menopause-related quality of life across all endocrine therapy subgroups, further supporting its effectiveness regardless of endocrine therapy type.
Lifestyle Medicine and Cancer Outcomes
Lifestyle interventions received significant attention at ASCO 2026. One study found that women with early-stage hormone receptor-positive breast cancer who followed a low glycemic index Mediterranean diet, incorporated 30 minutes of brisk walking into their daily routine, and took vitamin D supplementation experienced a 76% lower risk of recurrence compared with women who did not adopt these lifestyle modifications. Participants also experienced weight loss and improved blood glucose levels.
Multiple presentations highlighted the benefits of regular exercise throughout the cancer continuum, with growing evidence demonstrating that physical activity can improve physical functioning, reduce cancer-related fatigue, support cardiometabolic health, preserve muscle mass, enhance quality of life, and potentially improve long-term cancer outcomes.
The Future of Survivorship Care
ASCO 2026 reinforced that survivorship should be integrated throughout the entire cancer journey rather than treated as a post-treatment phase. Cancer survivors continue to experience challenges extending far beyond recurrence risk, including fatigue, anxiety, fear of recurrence, sexual dysfunction, menopausal symptoms, cognitive concerns, relationship difficulties, financial toxicity, and cardiometabolic complications.
As Dr. Al-Khaifi concluded: "The future of oncology will not be defined solely by how many years we add to life, but by how much life we add to those years. Survivorship is not an afterthought. It is one of the next frontiers in cancer care."